Amarantus Bioscience Holdings Inc (AMBS)

[zoomboom]

Concurrently with this announcement, Amarantus announced that it has executed an Exclusive Option Agreement with the University of Massachusetts Medical School ("UMMS") to license intellectual property recently developed at UMMS to advance Amarantus' diabetes diagnostic development and commercialization program using Amarantus' lead protein MANF as a biomarker for beta cell stress.
"The commercial potential for MANF as a diagnostic test that could identify patients who would most greatly benefit from Oral-lyn represents a significant market opportunity," said Gerald Commissiong, Amarantus' co-founder and Chief Operating Officer. "Unlike therapeutics, diagnostics can be commercialized in a relatively short period of time. This collaboration significantly improves Amarantus' development pipeline, targeting a key medical need in a multi-billion dollar market with no commercial-stage competition."
"The joint efforts of many players, starting from the discovery of a new use of MANF at UMass Medical School for diabetes, and the synergies of two highly committed organizations, has allowed us to generate a unique opportunity to launch a commercial development program for MANF as a biomarker of cellular stress and stressed beta cells in diabetes," said Dr. Fumihiko Urano, associate professor at the University of Massachusetts Medical School, who identified MANF's role in this area.

http://markets.financialcontent.com/stocks/news/read/18673668/Generex_Biotechnology_and_Amarantus_BioSciences_Announce_Oral